Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097370 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT00097370 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 78 participants.
The verdict
NCT00097370, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs and symptoms of Hypereosinophilic Syndrome.
Interventions
- DRUG mepolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2004-09-30 |
| Est. Completion | 2010-09-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097370
The ClinicalTrials.gov registry entry for NCT00097370 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mepolizumab is the first listed.
NCT00097370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097370 about?
NCT00097370 is a clinical study titled "Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome". This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the e...
What is the current status of trial NCT00097370?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2004-09-30. Estimated completion is 2010-09-29.
What interventions are being tested in trial NCT00097370?
The interventions under investigation include: mepolizumab (DRUG).
Who is sponsoring clinical trial NCT00097370?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.